Recent Trading Performance and Business Scale

Integer Holdings (ITGR) has recently attracted investor attention after a period of steady trading, with the stock last closing at $93.89 and showing mixed return patterns across different time frames.

Over the past day, the stock returned 0.83%, with gains of 3.22% over the past week, about 5.53% over the past month, and roughly 10.03% over the past 3 months. Year to date, the stock shows a 22.28% gain, while the total return over the past year reflects a decline of 23.39%. Over longer horizons, total returns are about 5.96% for 3 years and a 1.52% decline over 5 years.

Integer Holdings operates as a medical device contract development and manufacturing company serving multinational original equipment manufacturers across cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, advanced surgical, and portable medical markets. It generates revenue from procedures such as interventional cardiology, structural heart, neurovascular, vascular access, and various surgical applications, as well as from implantable devices, batteries, and components.

The company reports annual revenue of about $1.86b and net income of $141.80m, giving a sense of its current scale in the healthcare sector. Reported annual revenue growth is 3.80% with net income growth of 7.09%, and the company carries a market capitalization of roughly $3.16b.

Integer Holdings' recent momentum, including a 22.28% year to date share price return and 10.03% 3 month share price return, contrasts with a 23.39% decline in 1 year total shareholder return. This highlights a rebound that follows a weaker prior period.

If you are comparing Integer Holdings with other healthcare exposures, it can be useful to see how specialized technology is priced across the sector, starting with 39 healthcare AI stocks

With Integer Holdings trading near its recent close of $93.89 and sitting only about 4% below the average analyst price target, but at an estimated 30% discount to one intrinsic value model, is there still a potential entry point here or is the market already pricing in future growth?

Most Popular Narrative: 3.8% Undervalued

Based on the most followed narrative, Integer Holdings' fair value of $97.56 sits modestly above the recent $93.89 close. This frames the stock as slightly discounted rather than deeply mispriced.

Ongoing investments in manufacturing automation and operational excellence initiatives are yielding sequential gross and operating margin improvements, with expectations for further quarterly expansion through the year, underpinning continued net margin and earnings growth.

Want to see what turns steady revenue assumptions and modest margin gains into that fair value? The narrative leans on specific earnings, profitability and valuation multiples that are anything but random.

Result: Fair Value of $97.56 (UNDERVALUED)

However, the Integer Holdings story could still be tested if slower product ramps or any loss or renegotiation of major OEM contracts were to undercut the current fair value narrative.

Next Steps

With a mix of support and concern shaping the Integer Holdings view, it makes sense to move quickly and weigh both sides for yourself using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Integer Holdings?

If Integer Holdings has sharpened your interest in healthcare and manufacturing, do not stop here; broaden your watchlist with other focused ideas that match your style.

• Target dependable income by reviewing companies in the 8 dividend fortresses that may align with your approach to cash returns.
• Hunt for potential mispricings by scanning the 44 high quality undervalued stocks and see which stocks currently trade below one view of fair value.
• Prioritize capital preservation by assessing companies in the 71 resilient stocks with low risk scores and compare their profiles with your existing holdings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.